Portfolio Holdings Detail for ISIN IE00B3VWM098

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE

Holdings detail for ABUS

Show aggregate ABUS holdings

News associated with ABUS

Wall Street Zen Downgrades Arbutus Biopharma (NASDAQ:ABUS) to Hold

Wall Street Zen cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a buy rating to a hold rating in a research note issued to investors on Friday morning. Separately, Chardan Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a report on Monday, August 11th. […] - 2025-09-08 02:54:58

Arbutus Biopharma Corp. Q2 Earnings Summary

(RTTNews) - Below are the earnings highlights for Arbutus Biopharma Corp. (ABUS): - 2025-08-06 08:49:24

10,000 Shares in Arbutus Biopharma Corporation (NASDAQ:ABUS) Bought by Cyndeo Wealth Partners LLC

Cyndeo Wealth Partners LLC bought a new position in Arbutus Biopharma Corporation (NASDAQ:ABUS – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $35,000. Other hedge funds and other institutional investors have also […] - 2025-06-18 05:50:55

Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP grew its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 3.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 513,302 shares of the biopharmaceutical company’s stock after acquiring an additional 16,484 shares during the period. Wellington Management Group LLP’s holdings in Arbutus Biopharma were worth $1,678,000 […] - 2025-06-06 05:38:53

Millennium Management LLC Grows Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS)

Millennium Management LLC boosted its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 36.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 343,028 shares of the biopharmaceutical company’s stock after buying an additional 92,068 shares during the quarter. Millennium Management LLC’s […] - 2025-06-05 04:24:59

ProShare Advisors LLC Grows Position in Arbutus Biopharma Co. (NASDAQ:ABUS)

ProShare Advisors LLC increased its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 29.3% in the fourth quarter, HoldingsChannel reports. The firm owned 50,121 shares of the biopharmaceutical company’s stock after purchasing an additional 11,359 shares during the quarter. ProShare Advisors LLC’s holdings in Arbutus Biopharma were worth $164,000 as of its most […] - 2025-06-02 05:03:00

Deutsche Bank AG Increases Stake in Arbutus Biopharma Co. (NASDAQ:ABUS)

Deutsche Bank AG increased its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 77.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 171,766 shares of the biopharmaceutical company’s stock after acquiring an additional 75,212 shares during the quarter. Deutsche Bank AG’s holdings in Arbutus Biopharma were worth $562,000 at the end of […] - 2025-05-29 04:44:55

Northern Trust Corp Has $4.35 Million Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)

Northern Trust Corp increased its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 8.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,330,683 shares of the biopharmaceutical company’s stock after acquiring an additional 102,241 shares during the period. Northern Trust Corp’s holdings in Arbutus Biopharma were worth $4,351,000 at the end of […] - 2025-05-22 04:22:55

Invesco Ltd. Purchases 3,780 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

Invesco Ltd. grew its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 5.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 69,831 shares of the biopharmaceutical company’s stock after buying an additional 3,780 shares during the period. Invesco Ltd.’s holdings in Arbutus Biopharma […] - 2025-05-05 04:26:47

XTX Topco Ltd Acquires 22,568 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

XTX Topco Ltd raised its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 75.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 52,581 shares of the biopharmaceutical company’s stock after purchasing an additional 22,568 shares during the quarter. XTX Topco Ltd’s holdings in Arbutus Biopharma were worth $172,000 at the […] - 2025-04-29 05:24:53

Rockefeller Capital Management L.P. Has $349,000 Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)

Rockefeller Capital Management L.P. boosted its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 69.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 106,615 shares of the biopharmaceutical company’s stock after acquiring an additional 43,615 […] - 2025-04-24 06:00:57

Arbutus Biopharma Announces Acceptance of Five Abstracts for Presentation at EASL Congress 2025

Arbutus Biopharma announces five abstracts accepted for EASL Congress 2025, focusing on hepatitis B therapies and clinical trials. - 2025-04-23 03:10:26

Bank of Montreal Can Purchases 15,567 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

Bank of Montreal Can grew its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 3.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 455,880 shares of the biopharmaceutical company’s stock after purchasing an additional 15,567 shares during the quarter. Bank of Montreal Can’s holdings in Arbutus Biopharma were worth $1,491,000 as of […] - 2025-04-18 05:06:53

25,600 Shares in Arbutus Biopharma Co. (NASDAQ:ABUS) Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS acquired a new stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,600 shares of the biopharmaceutical company’s stock, valued at approximately $84,000. A number of […] - 2025-04-11 04:49:00

Mitsubishi UFJ Asset Management Co. Ltd. Decreases Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)

Mitsubishi UFJ Asset Management Co. Ltd. lessened its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 69,660 shares of the biopharmaceutical company’s stock after selling 12,287 shares during the period. […] - 2025-04-04 05:12:59

Intech Investment Management LLC Has $187,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS)

Intech Investment Management LLC increased its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 54.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 57,084 shares of the biopharmaceutical company’s stock after buying an additional 20,232 shares during the quarter. […] - 2025-03-28 07:12:50

Cibc World Markets Corp Takes $45,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS)

Cibc World Markets Corp bought a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 13,672 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Other institutional investors and hedge funds […] - 2025-03-28 06:18:44

Arbutus Biopharma Co. (NASDAQ:ABUS) Sees Large Growth in Short Interest

Arbutus Biopharma Co. (NASDAQ:ABUS – Get Free Report) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 8,410,000 shares, a growth of 16.6% from the February 13th total of 7,210,000 shares. Approximately 4.6% of the shares of the stock are […] - 2025-03-21 04:26:50

Arbutus Biopharma (NASDAQ:ABUS) Downgraded to “Sell” Rating by StockNews.com

StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. A number of other equities research analysts also recently commented on ABUS. Chardan Capital reissued a “buy” rating and issued a $5.00 price objective (up from $4.50) on shares […] - 2025-03-14 06:26:49

Comparing Arbutus Biopharma (NASDAQ:ABUS) & Akari Therapeutics (NASDAQ:AKTX)

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) and Akari Therapeutics (NASDAQ:AKTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership. Risk and Volatility Arbutus Biopharma has a […] - 2025-03-12 04:56:53

Arbutus Biopharma (NASDAQ:ABUS) Upgraded by StockNews.com to “Hold” Rating

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Other equities analysts have also issued reports about the company. JMP Securities boosted their price target on Arbutus Biopharma to $5.00 and gave the company a […] - 2025-03-07 04:10:47

Arbutus Biopharma (NASDAQ:ABUS) Cut to “Sell” at StockNews.com

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday. Other equities research analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of […] - 2025-02-27 04:15:04

China Universal Asset Management Co. Ltd. Buys 3,870 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

China Universal Asset Management Co. Ltd. grew its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,179 shares of the biopharmaceutical company’s stock after acquiring an additional 3,870 […] - 2025-02-04 06:53:07

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ABUS holdings

Date	Number of ABUS Shares Held	Base Market Value of ABUS Shares	Local Market Value of ABUS Shares	Change in ABUS Shares Held	Change in ABUS Base Value	Current Price per ABUS Share Held	Previous Price per ABUS Share Held
2025-09-26 (Friday)	103,291	USD 455,513	USD 455,513
2025-09-25 (Thursday)	103,291	USD 446,217	USD 446,217	0	USD -17,560	USD 4.32	USD 4.49
2025-09-24 (Wednesday)	103,291	USD 463,777	USD 463,777
2025-09-17 (Wednesday)	102,621	USD 454,611	USD 454,611	0	USD 3,079	USD 4.43	USD 4.4
2025-09-16 (Tuesday)	102,621	USD 451,532	USD 451,532
2025-09-12 (Friday)	101,951	USD 454,701	USD 454,701
2025-09-11 (Thursday)	101,951	USD 499,560	USD 499,560

Share Trades of ABUS by Blackrock for IE00B3VWM098

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-08-21	SELL	-335			3.580*		3.33 Profit of 1,116 on sale
2025-07-31	BUY	1,002			3.280*		3.33
2025-06-30	SELL	-670			3.090*		3.35 Profit of 2,246 on sale
2025-06-25	SELL	-335			3.340*		3.36 Profit of 1,124 on sale
2025-06-20	SELL	-670			3.430*		3.35 Profit of 2,248 on sale
2025-05-23	BUY	335			3.220*		3.34
2025-05-19	SELL	-335			3.130*		3.34 Profit of 1,120 on sale
2025-05-15	SELL	-1,005			3.120*		3.35 Profit of 3,365 on sale
2025-05-12	SELL	-335			3.350*		3.35 Profit of 1,123 on sale
2025-05-09	SELL	-335			3.230*		3.35 Profit of 1,124 on sale
2025-04-30	SELL	-335			3.550*		3.35 Profit of 1,121 on sale
2025-04-24	SELL	-670			3.340*		3.35 Profit of 2,241 on sale
2025-04-17	SELL	-335			3.150*		3.36 Profit of 1,124 on sale
2025-04-15	SELL	-1,005			3.160*		3.36 Profit of 3,380 on sale
2025-04-14	SELL	-1,005			3.280*		3.36 Profit of 3,381 on sale
2025-04-09	SELL	-1,340			3.170*		3.37 Profit of 4,522 on sale
2025-04-07	SELL	-2,345			3.005*		3.39 Profit of 7,946 on sale
2025-04-04	SELL	-3,360			3.230*		3.39 Profit of 11,394 on sale
2025-03-31	BUY	336			3.490*		3.39
2025-03-19	SELL	-672			3.310*		3.39 Profit of 2,279 on sale
2025-03-17	BUY	29,976			3.280*		3.40
2025-03-14	SELL	-1,464			3.300*		3.40 Profit of 4,978 on sale
2025-03-13	SELL	-490			3.320*		3.40 Profit of 1,667 on sale
2025-03-12	SELL	-8,330			3.190*		3.41 Profit of 28,375 on sale
2025-03-07	SELL	-490			3.310*		3.42 Profit of 1,678 on sale
2025-03-06	SELL	-735			3.370*		3.42 Profit of 2,517 on sale
2025-03-04	BUY	34,868			3.390*		3.42
2025-03-03	SELL	-151			3.420*		3.42 Profit of 517 on sale
2025-02-28	SELL	-36,642			3.450*		3.42 Profit of 125,470 on sale
2025-02-26	SELL	-246			3.440*		3.43 Profit of 843 on sale
2025-02-25	SELL	-738			3.450*		3.42 Profit of 2,527 on sale
2025-02-18	BUY	1,230			3.360*		3.43
2025-02-13	BUY	246			3.300*		3.45
2025-02-12	BUY	246			3.310*		3.45
2025-02-11	BUY	738			3.310*		3.46
2025-02-06	BUY	2,205			3.410*		3.47
2025-01-27	BUY	245			3.430*		3.53
2024-12-06	BUY	980			3.680*		3.51
2024-12-05	BUY	245			3.630*		3.49
2024-12-04	BUY	1,225			3.740*		3.45
2024-11-29	BUY	1,225			3.460*		3.45
2024-11-27	BUY	980			3.470*		3.41
2024-11-26	BUY	245			3.410*		0.00

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ABUS